Island Pharmaceuticals' U.S. Patent Achievement

Island Pharmaceuticals (ASX:ILA), an Australian antiviral drug company, announced the grant of a U.S. patent for ISLA-101. This patent, titled 'Method of viral inhibition,' covers the use of ISLA-101 to reduce dengue virus symptoms and expires in 2034.

Island Pharmaceuticals' Strategic Milestone

Island Pharmaceuticals has achieved a critical milestone with the granting of a U.S. patent for their lead drug, ISLA-101, enhancing their intellectual property portfolio. The patent, which expires in 2034, supports the company's Phase 2a/b clinical trials targeting dengue fever. The patent provides crucial protection for ISLA-101, potentially leading to a 'Priority Review Voucher' from the FDA, expediting drug approval processes. Island Pharmaceuticals, in collaboration with Monash University, continues to focus on drug repurposing for antiviral therapeutics, aiming to meet unmet medical needs.

Executive Insights on U.S. Patent Grant

The granting of this U.S. patent is a significant milestone for Island Pharmaceuticals. It not only strengthens our intellectual property portfolio but also supports our ongoing clinical trials for ISLA-101. This development underscores our commitment to addressing unmet needs in antiviral therapeutics, particularly for infectious diseases like dengue fever.